Welcome to our dedicated page for Adaptive Biotechnologies news (Ticker: ADPT), a resource for investors and traders seeking the latest updates and insights on Adaptive Biotechnologies stock.
Adaptive Biotechnologies Corporation reports company developments tied to immune-driven diagnostics and immune medicine. The commercial-stage biotechnology company applies a proprietary platform to translate adaptive immune system genetics into clinical products, with operating activity organized around Minimal Residual Disease (MRD) and Immune Medicine.
Recurring updates for ADPT include clonoSEQ MRD testing adoption, MRD revenue trends, pharma regulatory milestone revenue, operating expense guidance, and quarterly financial results. Company news also covers immune receptor and TCR-antigen data partnerships, autoimmune and cancer-related research applications, investor conference participation, and management commentary on the company’s diagnostic and drug-development collaborations.
Adaptive Biotechnologies (Nasdaq: ADPT) will announce its third-quarter 2022 financial results after market close on November 3, 2022. A conference call will follow at 1:30 p.m. PT / 4:30 p.m. ET, which will be available via live webcast on the company’s website. The company focuses on leveraging the adaptive immune system for clinical products aimed at diagnosing and treating diseases, including cancer and autoimmune disorders. Its proprietary platform is designed to decode the complexities of the immune system, enabling innovative diagnostics and therapeutics.
Adaptive Biotechnologies Corporation (Nasdaq: ADPT) announced a non-dilutive royalty financing agreement with OrbiMed, totaling up to $250 million. This deal aims to bolster Adaptive's balance sheet, which reported over $450 million in cash and marketable securities as of Q2 2022. The initial tranche of $125 million will support corporate purposes, with additional potential tranches of $75 million and $50 million for M&A. OrbiMed will receive a percentage of GAAP revenues, increasing to 10% with full funding. The partnership is designed to extend Adaptive’s cash runway and fuel growth initiatives.
Adaptive Biotechnologies Corporation (Nasdaq: ADPT) announced its participation in the Morgan Stanley Global Healthcare Conference in New York on September 12, 2022. The management team will take part in a fireside chat at 12:30 p.m. Eastern Time. Interested individuals can access a live and archived webcast via the company’s Investors section on their website. Adaptive Biotechnologies focuses on translating the genetics of the adaptive immune system into clinical products for diagnosing and treating various diseases, particularly cancer and autoimmune disorders.
Adaptive Biotechnologies reported a 13% year-over-year revenue increase for Q2 2022, totaling $43.7 million. The clonoSEQ test volume surged 53% compared to Q2 2021. The company's MRD revenue rose 38% to $21.3 million, while Immune Medicine revenue fell 3% to $22.4 million. Operating expenses increased 9% to $96.2 million, causing a net loss of $52.1 million. The firm maintains its full-year revenue guidance of $185 million to $195 million but has lowered expected operating expenses to $410 million to $415 million.
Adaptive Biotechnologies (Nasdaq: ADPT) has announced that clonoSEQ becomes the first assay to receive Medicare coverage for monitoring minimal residual disease (MRD) in patients with diffuse large B-cell lymphoma (DLBCL). This coverage expansion allows approximately 75% of treated DLBCL patients who are Medicare aged to access this test. The clonoSEQ assay utilizes circulating tumor DNA to provide insights on patient responses to treatment, potentially improving overall care. The coverage is effective immediately and complements existing Medicare coverage for other hematological malignancies.
Adaptive Biotechnologies Corporation (Nasdaq: ADPT) is set to report its second quarter 2022 financial results after the market closes on August 3, 2022. A conference call will follow at 1:30 p.m. PT / 4:30 p.m. ET. The company focuses on leveraging the adaptive immune system to develop diagnostic and therapeutic products for various diseases, including cancer and autoimmune conditions. The call will be accessible to registered participants, and a replay will be available on the company’s website within 24 hours.
Adaptive Biotechnologies (Nasdaq: ADPT) has launched T-Detect Lyme, a test designed to detect early Lyme disease with significantly higher sensitivity than existing antibody tests. This simple blood test identifies T cells activated by Borrelia burgdorferi, the Lyme disease-causing bacterium, thereby improving the accuracy of early Lyme diagnoses. With an approximate sensitivity of over 1.5 times that of standard testing, T-Detect Lyme could potentially identify cases that traditional tests miss, benefiting the estimated half a million newly infected individuals annually in the U.S.
Adaptive Biotechnologies (Nasdaq: ADPT) will present data at the ASCO Annual Meeting (June 3-7, 2022) highlighting the effectiveness of its clonoSEQ assay for measuring minimal residual disease (MRD) in blood cancers. clonoSEQ is the first FDA-cleared test for MRD in chronic lymphocytic leukemia (CLL), multiple myeloma (MM), and B-cell acute lymphoblastic leukemia (B-ALL). The data support clonoSEQ's role in assessing treatment response and patient outcomes, marking a significant step towards standardizing MRD assessment in lymphoid cancers.
Adaptive Biotechnologies Corporation (Nasdaq: ADPT) will participate in two upcoming investor conferences. The William Blair 42nd Annual Growth Stock Conference takes place on June 8 at 3:20 p.m. CT in Chicago, IL, while the Goldman Sachs 43rd Annual Global Healthcare Conference is scheduled for June 15 at 10:00 a.m. PT in Rancho Palos Verdes, CA.
Live and archived webcasts will be accessible via their website.
Adaptive Biotechnologies reported a Q1 2022 revenue of $38.6 million, a slight 0.5% increase year-over-year. The clonoSEQ test volume surged by 45% compared to Q1 2021. However, MRD revenue saw a 3% decline to $17.8 million. Operating expenses rose significantly by 28% to $101.7 million, resulting in a net loss of $62.8 million, compared to $40.6 million in Q1 2021. The company maintains its full-year revenue guidance of $185 million to $195 million.